Learn more about our Advocacy work.
This week, AdvaMed, The Medtech Association®, sent a letter to Congressional leaders regarding the proposed payment cuts to office-based specialist physicians under the Medicare Physician Fee Schedule. AdvaMed® was joined…
Scott Whitaker, president and CEO of AdvaMed®, recently chatted with Joe Mullings, chairman and CEO of The Mullings Group, about the impact of the medtech industry and the importance of…
Today, AdvaMed® marked the one year anniversary of the signing of the bipartisan CHIPS and Science Act and called on the Biden Administration to ensure, as implementation moves forward, that…
Ethylene oxide sterilization ensures billions of pieces of medical technology are sterile for patients in every medical setting, in surgical procedures from c-sections to knee replacements.
This week, AdvaMed, The Medtech Association®, praised ongoing legislative efforts to develop a pathway for Medicare coverage for FDA-approved breakthrough technologies during a House Committee on Energy and Commerce Subcommittee…
According to a senior toxicologist in a RealClearPolicy op-ed, the EPA draws unreasonable conclusions about the health risks of the ethylene oxide used to sterilize medical technology.
AdvaMed, The Medtech Association®, released the following statement from President and CEO Scott Whitaker on the recently issued proposed Transitional Coverage for Emerging Technologies (TCET) rule.
AdvaMed, The Medtech Association®, today called on the Biden Administration to implement a proposal to create a predictable pathway to national Medicare coverage for breakthrough medical technologies. The announcement comes…
It is easy to take for granted the role medtech plays in our everyday lives. From heart valves, imaging equipment, and pacemakers to continuous glucose monitors, we rely on these technologies to…
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA).